Morgan Stanley Reiterates Overweight on Neurocrine Biosciences, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a $130 price target.

July 11, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Neurocrine Biosciences and maintained a $130 price target.
The reiteration of an Overweight rating by a major financial institution like Morgan Stanley indicates a positive outlook for Neurocrine Biosciences. The maintained price target of $130 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100